Late-Window Stroke: Hyperglycemia Doesn’t Alter EVT Benefit
The International Journal of Stroke recently shared a post on X:
”Just Accepted! Study in those with acute ischemic stroke and large vessel occlusion of the anterior circulation. Results show hyperglycaemia does not modify the efficacy of endovascular therapy in the late time window.”
Read the full article here.
Hyperglycemia has long been the unwelcome guest at the stroke table, often associated with worse outcomes and suspected of meddling with treatment effects—especially in early endovascular therapy (EVT).
Naturally, one might expect it to play a similarly disruptive role in patients treated in the late window (6 to 24 hours after symptom onset or last known well).
But in the study of anterior circulation large vessel occlusion stroke, Clemens Kersten et al. showed that hyperglycemia had surprisingly little to say.
Regardless of admission glucose levels, the benefit of EVT remained unchanged.
In conclusion, no evidence that admission glucose or hyperglycemia modifies the benefit of EVT in this population, suggesting EVT efficacy remains consistent across a range of glucose levels in the late window setting.
Stay updated on the advancements in science in the field of thrombosis with Hemostasis Today.
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial